BCRX
BioCryst Pharmaceuticals, Inc.
14.20
-
0.05
0.35%
14 x 14.27
12 x 14.30
bid
ask
10:07 AM
timesize
Bearish
30
Bullish
77
sentiment
14.14
day range
14.37
7.61
52 week range
19.99
Prev Close14.25
Open14.34
Low14.14
High14.37
Volume201.92K
Avg. Volume3.10M
Market Cap2.65B
Inst. Own83.89%
Beta2.20
Short Ratio12.23
Div & Yield0.00 /
EPS-1.07
P/E
1yr Target18.60
50day MA11.44
200day MA12.90
^DJI
Dow Jones Industrial Average
33853.90
10:08 AM
-
126.40
0.37%
^IXIC
NASDAQ Composite
12898.90
10:07 AM
-
39.20
0.30%
^GSPC
S&P 500
4264.85
10:07 AM
-
9.19
0.22%
AAPL
Apple Inc.
173.44
10:07 AM
8 x 174.01
9 x 173.90
-
1.11
0.64%
GOOG
Alphabet Inc.
120.06
10:07 AM
9 x 120.08
40 x 120.12
-
0.26
0.21%
AMZN
Amazon.com, Inc.
141.11
10:08 AM
10 x 141.13
9 x 141.18
-
0.99
0.70%
MSFT
Microsoft Corporation
290.06
10:07 AM
13 x 289.96
8 x 290.03
-
1.26
0.43%
BABA
Alibaba Group Holding Limited
89.06
10:08 AM
13 x 88.94
10 x 88.95
-
0.71
0.79%
NFLX
Netflix, Inc.
240.99
10:07 AM
10 x 240.00
9 x 240.41
-
0.16
0.07%
TSLA
Tesla, Inc.
909.00
10:07 AM
10 x 911.47
14 x 911.87
-
2.99
0.33%
NVDA
NVIDIA Corporation
184.68
10:07 AM
11 x 184.28
8 x 184.12
+
1.33
0.72%
AMD
Advanced Micro Devices, Inc.
98.33
10:08 AM
8 x 98.25
8 x 98.25
+
0.06
0.06%
MU
Micron Technology, Inc.
61.99
10:07 AM
14 x 61.75
9 x 61.77
+
0.38
0.61%
SPY
SPDR S&P 500 ETF Trust
425.90
10:07 AM
10 x 426.18
11 x 426.10
-
0.75
0.18%
TQQQ
ProShares UltraPro QQQ
37.03
10:07 AM
8 x 36.96
14 x 36.97
-
0.27
0.71%
BRK-A
Berkshire Hathaway Inc.
455596.00
10:07 AM
10 x 456582.00
11 x 457253.00
-
1682.00
0.37%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
News
...
| 2022-08-18 | NDAQ:BCRX | Press Release | BioCryst Pharmaceuticals Inc. | stockhouse.com • |
| Russell Investments Group Ltd. Has $1.31 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) | defenseworld.net • |
| BioCryst Pharmaceuticals Inc (BCRX) Down 3.35% in Premarket Trading | investorsobserver.com • |
| Ginkgo Bioworks Holdings Inc (DNA) Down 3.48% in Premarket Trading | investorsobserver.com • |
| BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia | marketscreener.com • |
| State Board of Administration of Florida Retirement System Sells 13040 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) | defenseworld.net • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
| 2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-08-08 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Barclays | Upgrade | Equal-Weight | |
| 2022-08-05 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| 2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2022-04-12 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | HEGGIE THERESA | Director | 30.23K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
| 2022-06-06 | INGRAM ROBERT ALEXANDER | Director | 95.00K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-06-29 | Blackrock Inc. | 13.99M | 199.32M | 7.52% |
| 2022-06-29 | Vanguard Group, Inc. (The) | 13.81M | 196.79M | 7.43% |
| 2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 181.13M | 6.84% |
| 2022-03-30 | State Street Corporation | 7.46M | 106.34M | 4.01% |
| 2022-06-29 | Pictet Asset Management SA | 6.05M | 86.17M | 3.25% |
| 2022-06-29 | Fisher Asset Management, LLC | 5.22M | 74.34M | 2.81% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-06-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 7.26M | 103.50M | 3.91% |
| 2022-03-30 | Vanguard Total Stock Market Index Fund | 5.26M | 74.97M | 2.83% |
| 2022-06-29 | iShares Russell 2000 ETF | 4.17M | 59.43M | 2.25% |
| 2022-05-30 | Fidelity Select Portfolios - Biotechnology | 4.19M | 59.74M | 2.25% |
| 2022-04-29 | Lord Abbett Developing Growth Fund | 2.45M | 34.94M | 1.32% |
| 2022-03-30 | Vanguard Extended Market Index Fund | 2.39M | 34.03M | 1.29% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
$BCRX I sure hope @Imakook gives us some direction today
-
$BCRX I had 31K shares sitting right here a few day’s ago…does this concern any of you?
-
-
$BCRX Great we’ve got Imacouk sharing knowledge this morning it’s gona be a good day?
-
$BCRX Where is this guy mike smith getting subway sandwiches for $4.00 in Dallas there all $5.50.
-
$BCRX Well since my account is going to hell in a hand basket and my family relies on me I’m going to go to my beach house for the week and think about it………now what was I thinking about? Heaven help us all.
-
$BCRX $4.67 how wet it is!
-
$BCRX Wow Mikey this thing is gona take off …run and tell your mommy
-
$BCRX I needed a smile…thanks
-
$BCRX
Who’s it gonna bbbe -
$BCRX Let my people go you raskley rats
-
$BCRX BINGO
-
$BCRX Creatine levels are leveling out …good news
-
‘$BCRX I’m glad to see someone else is concerned about something not just the Sea Turd
-
$BCRX @Harrington with all the trash you spout this is about as far as your going to get buddy
-
$BCRX I think it’s time
-
$BCRX BASTARDS BASTARDS BASTARDS……….
-
$BCRX So much for that 1k share add at “this is going to be the bottom” price of 9.97.
-
$BCRX You ever felt like you’ve been stabbed in the back…just wondering?
-
BioCryst Pharmaceuticals Inc (BCRX) Down 3.35% in Premarket Trading
investorsobserver.com • -
Ginkgo Bioworks Holdings Inc (DNA) Down 3.48% in Premarket Trading
investorsobserver.com • -
BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
marketscreener.com • -
Top 5 2nd Quarter Trades of Biondo Investment Advisors, LLC
gurufocus.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com •
